

12 March 2025

Argent BioPharma Ltd.

(Argent BioPharma or the Company)

Exclusive Agreement for Malta Manufacturing Facility

Highlights:

- **Argent BioPharma has entered into an agreement with Dr. Shlomo Sadoun, granting him exclusive rights to facilitate a commercial transaction for Argent BioPharma's Malta-based manufacturing facility.**
- **Dr. Sadoun is the CEO of SK-Pharma, a leading pharmaceutical company specialising in innovative healthcare solutions, and has also served as a corporate advisor to Argent BioPharma, leveraging his expertise in strategic partnerships and pharmaceutical commercialisation.**
- **The agreement aims to establish potential new contract manufacturing or supply and distribution partnerships outside the Company's product portfolio.**
- **Under the Term Sheet, Argent BioPharma must receive a minimum consideration of US\$1 million, payable from the counterparty's profits, aside from the ongoing ability to produce Argent BioPharma's product as needed.**
- **The exclusivity period for Dr. Sadoun is three months from the date of signing.**
- **Argent BioPharma will retain all licenses and maintain minimal operational activity at the facility during the exclusivity period to support potential transactions.**

Argent BioPharma is pleased to announce that it has signed an agreement with Dr. Shlomo Sadoun, granting him exclusive rights to facilitate a commercial transaction for the Company's Malta-based GMP-certified manufacturing facility (**Facility**).

Under the agreement, Dr. Sadoun will have a three-month exclusivity period to introduce a potential investment, contract manufacturing, or supply and distribution deal that meets the following key conditions:

- The transaction must not negatively impact Argent BioPharma's relationship with Maltese government authorities.
- The minimum consideration for Argent BioPharma will be at least US\$1 million, payable from profits generated by the counterparty.
- Any final agreement will require approval by Argent BioPharma's corporate governance bodies, in compliance with regulatory and legal requirements.
- Argent BioPharma will retain the ability to produce its product portfolio in Malta at cost following the deal.

During the exclusivity period, Argent BioPharma remains committed to maintaining the necessary licenses and regulatory approvals for the Malta-based manufacturing facility, ensuring minimal operational activity to support potential transactions. The Company will not be liable for any consideration under the agreement.

This agreement aligns with Argent BioPharma's broader strategic initiative to optimise its global manufacturing operations and unlock new commercial opportunities through strategic partnerships and asset optimisation.

Following the recent collaboration agreement with ECCPharm¹, Argent BioPharma intends to transition the manufacturing of its proprietary portfolio to ECCPharm's EU-GMP-certified facility. The Company anticipates this

¹ Refer to Announcement dated 5 March 2025.

move will result in significant cost efficiencies and improving the cost of goods sold for Argent BioPharma under the structured agreement with ECCPharm.

With its EU-GMP-certified Malta facility now available, Argent BioPharma is actively repositioning the site as a Contract Manufacturing Operations (CMO) service, catering to pharmaceutical companies seeking a specialised, cost-effective, and boutique liquid dose manufacturing solution within the EU.

Next Steps:

Dr. Sadoun will engage potential investors, strategic partners, and industry stakeholders to secure a commercially viable deal within the exclusivity period. Further updates will be provided to the market as negotiations progress.

Roby Zomer, CEO & Managing Director of Argent BioPharma, commented: *"We are pleased to engage Dr. Sadoun to explore strategic options for our Malta-based manufacturing facility. This agreement provides a structured framework to assess opportunities that align with our long-term vision while ensuring value for shareholders. We look forward to evaluating potential transactions that enhance our operational and financial position."*

Dr. Shlomo Sadoun, CEO of SK-Pharma and exclusive facilitator of the Malta facility transaction, commented: *"I am excited to collaborate with Argent BioPharma in unlocking the full potential of its EU-GMP-certified Malta facility. This site presents a unique opportunity for pharmaceutical companies seeking a cost-efficient, high-quality liquid dose manufacturing solution within the EU. With Argent's strategic shift towards clinical development and regulatory expansion, transforming this facility into a contract manufacturing hub will create significant value for both Argent and potential industry partners."*

—Ends—

Authorised for release by the board of directors, for further information please contact:

Argent BioPharma
Roby Zomer
CEO & Managing Director
+61 8 6555 2950
info@argentbiopharma.com

Argent BioPharma
Rowan Harland
Company Secretary
+61 8 6555 2950
info@argentbiopharma.com

About Argent BioPharma

Argent BioPharma Limited (ASX: RGT; OTCQB: RGTLF) is an innovative clinical-stage biopharmaceutical company specialising in neuroimmunology, developing advanced nano-medicines to address unmet medical needs in central nervous system (CNS) disorders and immune-related conditions. By leveraging cutting-edge technologies, including the Neuro-Immune Modulatory (NIM) System and its role in coordinating nervous and immune responses, Argent BioPharma's robust pipeline—featuring lead candidates like CannEpil®, CogniCann®, and CimetrA®—targets complex diseases where effective treatments are lacking. Through a commitment to science-driven innovation and patient-centered outcomes, Argent BioPharma is reshaping the future of care for chronic, inflammatory, and neurodegenerative diseases.

Follow us through our social media channels:

LinkedIn: Argent BioPharma
Twitter: @ArgentBioPharma
Facebook: Argent BioPharma

Argent BioPharma Ltd
Suite 1, 295 Rokeby Road
Subiaco, WA 6008, Australia

 +61 8 6555 2950

 info@argentbiopharma.com